



**Date:** February 22, 2021  
**To:** Ordering Providers – All Zones  
Alberta Precision Laboratories – All Staff  
Dynalife – All Staff  
**From:** Clinical Biochemistry Section, South Sector, Alberta Precision Laboratories (APL)  
**Re:** Change in therapeutic range for primidone

---

**PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE**

---

**Key Message:**

- As of March 1, 2021, the therapeutic range for primidone is changing from 23-55 µmol/L to 23-46 µmol/L

**Why this is Important:**

- All primidone results of 47 µmol/L or greater will be flagged as 'HIGH'.

**Background:**

- As part of provincial standardization in preparation for Connect Care, the provincial laboratory toxicology working group aligned primidone reporting based on the following clinical practice guideline: Patsalos PN et al. 2008. Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. *Epilepsia*. 2008 Jul;49(7):1239-76.

**Action Required:**

- Be aware of the changes to therapeutic range and result flagging

**Inquiries and feedback may be directed to:**

- Lawrence de Koning, PhD, Clinical Biochemist, Alberta Children's Hospital, South Sector APL, (403) 955-2277, [Lawrence.dekoning@aplabs.ca](mailto:Lawrence.dekoning@aplabs.ca)
- Jessica Boyd, PhD, Clinical Biochemist, Analytical Toxicology, South Sector APL, (403) 770-3549, [jessica.boyd@aplabs.ca](mailto:jessica.boyd@aplabs.ca)

**This bulletin has been reviewed and approved by:**

- Hossein Sadrzadeh, PhD, Section Chief, Clinical Biochemistry, South Sector, APL
- Ethan Flynn, MD, Acting Associate Medical Director, South Sector, APL